BRIEF published on 03/14/2025 at 07:35, 1 year ago Sensorion: 2024 Review and Outlook for 2025 Financial Results Investments SENS-401 SENS-501 Gene Therapies
PRESS RELEASE published on 03/14/2025 at 07:30, 1 year ago Informations privilégiées / Communiqué sur comptes, résultats Sensorion présente ses résultats financiers pour l’exercice 2024, fait le point sur ses activités et annonce la mise à disposition du rapport annuel. Renforcement financier, essais cliniques avancés Résultats Financiers Innovation Scientifique Thérapie Génique Études Cliniques Sensorion
PRESS RELEASE published on 03/14/2025 at 07:30, 1 year ago Inside Information / News release on accounts, results Sensorion reports full-year 2024 results and provides corporate update with significant milestones achieved in gene therapy clinical trials and financial highlights. Company well positioned for growth in 2025 Clinical Trials Financial Highlights Gene Therapy Full-year Results Sensorion
BRIEF published on 03/07/2025 at 07:35, 1 year ago Sensorion conclut le recrutement pour l'essai NOTOXIS sur le SENS-401 Essai Clinique Sensorion SENS-401 Cisplatine Ototoxicité
BRIEF published on 03/07/2025 at 07:35, 1 year ago Sensorion Completes Recruitment for NOTOXIS Trial of SENS-401 Clinical Trial Sensorion SENS-401 Cisplatin Ototoxicity
PRESS RELEASE published on 03/07/2025 at 07:30, 1 year ago Informations privilégiées / Autres communiqués Sensorion annonce la fin du recrutement des patients dans NOTOXIS, essai clinique Phase 2a SENS-401 pour prévenir ototoxicité cisplatine. Résultats NOTOXIS attendus fin 2025 Phase 2a Sensorion SENS-401 Ototoxicité NOTOXIS
PRESS RELEASE published on 03/07/2025 at 07:30, 1 year ago Inside Information / Other news releases Sensorion completes patient enrollment in NOTOXIS Phase 2a Clinical Trial of SENS-401 for Cisplatin-Induced Ototoxicity prevention, targeting a significant unmet medical need Clinical Trial Sensorion SENS-401 NOTOXIS Cisplatin-Induced Ototoxicity
BRIEF published on 02/21/2025 at 07:35, 1 year ago Sensorion's SENS-501 Clinical Trial Progresses with Positive DMC Recommendation Gene Therapy Clinical Trial Sensorion Hearing Loss SENS-501
BRIEF published on 02/21/2025 at 07:35, 1 year ago L'essai clinique SENS-501 de Sensorion progresse avec une recommandation DMC positive Essai Clinique Thérapie Génique Sensorion Perte Auditive SENS-501
PRESS RELEASE published on 02/21/2025 at 07:30, 1 year ago Inside Information / Other news releases Sensorion receives positive recommendation from Data Monitoring Committee for Audiogene Phase 1/2 clinical trial of SENS-501 gene therapy program to treat congenital deafness linked to OTOF gene mutations Gene Therapy Sensorion Audiogene Deafness Data Monitoring Committee
Published on 03/20/2026 at 03:10, 5 hours 29 minutes ago Future Fuels Announces Filing of Amended and Restated Life Offering Document
Published on 03/20/2026 at 00:20, 8 hours 19 minutes ago Prospect Ridge To Host Investor Webinar With Presentation And Audience Q&A
Published on 03/20/2026 at 00:20, 8 hours 19 minutes ago Reeflex Solutions Inc. Announces Revocation of Management Cease Trade Order
Published on 03/19/2026 at 21:16, 11 hours 23 minutes ago Unusual Machines, Inc. Announces Proposed Public Offering
Published on 03/19/2026 at 14:20, 18 hours 19 minutes ago CBMJ CEO Rips Legacy Liberal Media Over Iran Coverage on The Schaftlein Report
Published on 03/20/2026 at 08:00, 39 minutes ago Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
Published on 03/20/2026 at 07:45, 54 minutes ago Global Talent Summit Week Looks Ahead to the Future Workplace in the AI Era
Published on 03/19/2026 at 18:00, 14 hours 39 minutes ago Filing of the 2025 Universal Registration Document
Published on 03/19/2026 at 18:00, 14 hours 39 minutes ago Mise à disposition du Document d’Enregistrement Universel 2025
Published on 03/19/2026 at 08:45, 23 hours 54 minutes ago Deezer et Sonos renouvellent et étendent leur partenariat stratégique
